Aeterna Zentaris has recruited the first patient in a Phase IIa trial of AEZS-130, a ghrelin agonist, in cancer cachexia patients.
AEZS-130 is a novel orally-active small molecule that stimulates the secretion of growth hormones by binding to the ghrelin receptor (GHSR-1a).
The double-blind, randomised study, being conducted under a cooperative research and development agreement between Aeterna Zentaris and the Michael E DeBakey Veterans Affairs Medical Center, is designed to test the effects of different doses of AEZS-130 in 18 to 26 patients with cancer-cachexia.
Aeterna Zentaris president and CEO Juergen Engel said; "Because cachexia is very common among cancer patients, our oral ghrelin agonist, AEZS-130, could represent a novel treatment option for many of the 1.5m people diagnosed with cancer each year, in the US alone."
Following the safety and efficacy analysis at each dose level versus a placebo, which involves three sequential groups receiving differing doses of AEZS-130, the decision to either decrease or increase the dose will be taken.
Adequate efficacy is defined in the study as a =0.8kg of body weight gain or a =50ng/mL increase in plasma IGF-1 levels.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The safety and efficacy of repeated oral administration of AEZS-130 at different doses daily for one week, in view of developing a treatment for cachexia, is the primary objective of the placebo-controlled study.
Other secondary objectives include food intake and changes in appetite, muscle strength, energy expenditure, reward from food and functional brain connectivity.